Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | GD2IL18CART |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
GD2IL18CART comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets GD2 and an inducible IL-18 that depends on target engagement, which potentially increases cytokine production and lysis of GD2-expressing cells, leading to tumor growth inhibition (PMID: 38593230). |
| DrugClasses | GD2 Immune Cell Therapy 7 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + GD2IL18CART | Bevacizumab GD2IL18CART | 0 | 1 |
| GD2IL18CART | GD2IL18CART | 0 | 0 |